News and blog posts

06

Apr 2020

On March 30, 2020, the French High Authority for Health, has published the opinion of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS) regarding the Impella 5.0 device. The clinical added value was graded with level II (important) for the post-cardiotomy cardiogenic shock indication. After the negotiation with CEPS, Impella might be the first short-term VAD to enter add-on reimbursement list LPPR. Read more

03

Apr 2020

The report presents a summary of the reimbursement situation for minimally invasive treatment of prostate cancer in Europe. The following procedures are considered under the scope of analysis: high intensity focused ultrasound (HIFU), cryoablation, focal laser ablation, radiofrequency ablation, microwave thermal ablation of the prostate. Open and laparoscopic radical prostatectomy, as well as external radioation therapy and low-dose-rate barchytherapy, are considered as comparators. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey. Read more

03

Apr 2020

The report presents a summary of the reimbursement situation for the use of minimally invasive treatment of lung cancer in Europe. The following procedures ware considered under the scope of analysis: cryotherapy, microwave ablation, photodynamic therapy, radiofrequency ablation of lung. Open and VATS lobectomy will be considered as a comparator. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey. Read more

03

Apr 2020

In March 2020, the entity managing the Swiss DRG system, SwissDRG, released several announcements about the changes related to the COVID19. The announcements concern diagnosis coding of COVID19, and the reimbursement changes required to adequately cover the care for the new disease. Read more

02

Apr 2020

The report presents a summary of the reimbursement situation for occipital nerve stimulation in Europe. The following indications are considered: migraine with aura; cluster headache syndrome. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey. Read more

02

Apr 2020

The report presents a summary of the reimbursement situation for mechanical ventilation in Europe. The following clinical indications are considered: acute community-acquired viral pneumonia complicated with acute respiratory failure; severe sepsis due to acute community-acquired viral pneumonia with multiorgan failure (cardiac, respiratory and renal); acute hemorrhagic stroke with the development of com. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey. Read more

02

Apr 2020

In February 2020, the Andalusian Health Technology Assessment Department published an assessment report on the evaluation of effectiveness and safety of epicardial closure of left atrial appendage using clips by minimally invasive surgery for thromboembolism prevention in patients with atrial fibrillation. The scientific evidence about the effectiveness and safety of the left atrial appendage closure through minimally invasive epicardial clipping is inadequate and insufficient; further research is needed. Read more

01

Apr 2020

The report presents a summary of the reimbursement situation for the use of negative pressure wound therapy (NPWT) (procedure and medical aid) in Europe. The following clinical indications are considered: diabetic foot ulcer; venous leg ulcer; pressure ulcer. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey. Read more

01

Apr 2020

Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) has introduced two new service codes for physicians’ teleconsultation regarding COVID-19. INAMI Insurance Committee established a reimbursement fee of €20. Read more

31

Mar 2020

On 22 January 2020, the consultation on proposals for a national tariff for 2020/21 closed. However, the release of the 2020/21 tariff has been postponed due to the NHS response to COVID-19. NHS will report publishing details at the earliest opportunity. Read more

30

Mar 2020

On March 4, 2020, the List of Analyses (AL/EA) and the Services Ordinance (KLV/OPre) were updated in Switzerland. On April 1, 2020, the KLV/OPre, the AL/EA, and the List of Medical Aids (MiGel/EMAp) will be updated in Switzerland. Read more

27

Mar 2020

In March 2020, Swedish Skåne Region has released a report for the use of hydrogel spacer in radiotherapy of prostate cancer. Treatment with hydrogel spacer provides long-term improved quality of life, but the scientific base is limited. The scientific evidence base on the positive effect of the spacer in erectile function is insufficient. Read more